BLUEJETBlue Jet Healthcare Ltd.

₹663.25-2.15%

Market Cap

₹11,744.48 Cr

Stock P/E

84.85

ROCE

56.68%

ROE

51.06%

Book Value

₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

POSITIVES

•
Revenue momentum remains robust with 118% YoY growth in Q1 revenue.
•
EBITDA and PAT expanded meaningfully on a YoY basis (178% and 114% respectively).

NEGATIVES

•
Gross margin compression in Q1 driven by inventory and mix, indicating margin volatility.
•
Significant one-time GST impact on EBITDA and a softer forex environment dent margins.

Peers Summary

Growth Outperformer

Blue Jet Healthcare Ltd. stands out as a growth outperformer with the highest ROE in its peer group, showcasing impressive profitability metrics. While it has a high PE ratio, its strong earnings growth potential justifies this valuation. In contrast, several peers exhibit weaker growth, higher valuations, or financially risky profiles, making Blue Jet a compelling investment choice in the Pharmaceuticals & Drugs sector.

Key Points

• Blue Jet has the highest ROE (51.06%) among its peers, indicating strong profitability.
• Several peers exhibit high PE ratios with limited growth, suggesting potential overvaluation.
• Financially weak companies in the sector have low margins and high debt levels, highlighting risk.

Top Performers

Blue Jet Healthcare Ltd.

Highest ROE (51.06%) and strong earnings potential.

Cipla Ltd.

Strong profitability metrics with a low PE ratio (23.73) relative to its growth.

Dr. Reddy's Laboratories Ltd.

Solid growth trajectory with a low PE ratio (15.50) and good ROE.

Explore

Watchlists